The company has also added a group of industry experts to its advisory board.
Douglas most recently led Bridge4Bio, a business consultancy. Prior to this he was managing director and president of Hoefer, a division of Harvard Bioscience.
The new members of the advisory board are Lori Kunkel, who has held various senior positions in the industry, including chief medical officer at Proteolix/Onyx Pharmaceuticals and vice president of clinical development at Xenocor, and Paul Nowak, ceo of Biotix Holdings.
Nowak has spent the majority of his career at VWR International, a global distributor of laboratory supplies, where he held many positions, including ceo and president.
BioCision appoints coo
Also expands corporate advisory board
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra